BECTON, DICKINSON AND COMPANY Becton, Dickinson and Company Share Price
Equities
BDX
US0758871091
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 228.8 USD | -0.68% |
|
-3.18% | -6.17% |
| Sales 2024 * | 20.24B 1,589B | Sales 2025 * | 21.42B 1,682B | Capitalization | 66.12B 5,192B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.11B 166B | Net income 2025 * | 2.48B 195B | EV / Sales 2024 * | 3.91 x |
| Net Debt 2024 * | 12.96B 1,018B | Net Debt 2025 * | 10.62B 834B | EV / Sales 2025 * | 3.58 x |
| P/E ratio 2024 * |
31.9
x | P/E ratio 2025 * |
28.4
x | Employees | 73,000 |
| Yield 2024 * |
1.64% | Yield 2025 * |
1.68% | Free-Float | 77.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on Becton, Dickinson and Company
More recommendations
More press releases
| 1 day | -0.68% | ||
| 1 week | -3.18% | ||
| Current month | -2.48% | ||
| 1 month | -2.16% | ||
| 3 months | -7.07% | ||
| 6 months | -4.23% | ||
| Current year | -6.17% |
1 week
228.09
238.17
1 month
228.09243.28
Current year
228.09249.89
1 year
228.09287.32
3 years
215.90287.32
5 years
197.75287.32
10 years
112.15287.32
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Polen
CEO | Chief Executive Officer | 50 | 31/12/08 |
| Director of Finance/CFO | 52 | 05/09/21 | |
| Chief Tech/Sci/R&D Officer | 48 | 31/12/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bertram Scott
BRD | Director/Board Member | 73 | 23/09/02 |
Catherine Burzik
BRD | Director/Board Member | 73 | 28/01/13 |
| Director/Board Member | 69 | 25/07/10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.40% | 254 M€ | +13.10% | - | |
| 2.78% | 2 M€ | 0.00% | - | |
| 2.47% | 6 M€ | +16.84% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/05/24 | 228.8 | -0.68% | 1,373,384 |
| 23/05/24 | 230.4 | -1.75% | 1,302,586 |
| 22/05/24 | 234.4 | -0.17% | 1,364,186 |
| 21/05/24 | 234.9 | -0.96% | 1,557,704 |
| 20/05/24 | 237.1 | +0.35% | 967,074 |
Delayed Quote Nyse, May 24, 2024 at 09:00 pm
More quotes
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Calendar
09/06/2024
- Ex-dividend day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
228.8
USD
Average target price
279
USD
Spread / Average Target
+21.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.17% | 66.12B | |
| -5.56% | 181B | |
| -0.11% | 108B | |
| +2.64% | 50.65B | |
| +6.58% | 43.66B | |
| +4.91% | 41.3B | |
| +21.98% | 31.6B | |
| +14.45% | 25.03B | |
| -5.81% | 24.16B | |
| -4.35% | 23.95B |
- Stock Market
- Equities
- BDX Stock
